推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 位于浙江紹興濱海新城的浙江醫(yī)藥昌?；?，目前大部分已建成，該基地將承擔(dān)四部分產(chǎn)能的生產(chǎn)：維生素、生物藥、創(chuàng)新藥以及制劑，其中制劑的生產(chǎn)為布局的重中之重?！ ?/p>
“原料藥我們現(xiàn)在繼續(xù)生產(chǎn)，但是制劑、保健品這塊現(xiàn)在是我們的戰(zhàn)略方向?！睆垏?guó)鈞介紹，按照公司的“雙輪驅(qū)動(dòng)”戰(zhàn)略，在原料藥繼續(xù)生產(chǎn)的前提下，加速制劑生產(chǎn)，并意欲拓展出口渠道?！ ?/p>
記者在昌?；亓私獾剑壳霸摶氐闹苿S區(qū)正在安裝階段，未來將主攻出口制劑、國(guó)內(nèi)制劑以及國(guó)內(nèi)保健品三大塊。張國(guó)鈞介紹，制劑廠區(qū)預(yù)計(jì)今年下半年會(huì)試運(yùn)行，明年上半年投產(chǎn)?！ ?/p>
“浙江藥企的原料藥生產(chǎn)曾經(jīng)在全國(guó)領(lǐng)先，受惠于訂單出口優(yōu)勢(shì)，以前我們的產(chǎn)品走出去也很容易，因?yàn)樵纤幧a(chǎn)污染重、利潤(rùn)低，國(guó)外的企業(yè)不愿意生產(chǎn)，但是近幾年生產(chǎn)成本、環(huán)保壓力都在上去，利潤(rùn)極速下滑，我們不得不尋求轉(zhuǎn)型。”張國(guó)鈞對(duì)記者透露。
實(shí)際上，受原料藥利潤(rùn)壓縮的拖累，作為老牌醫(yī)藥企業(yè)，浙江醫(yī)藥大宗原料藥VE巨頭地位早在前幾年就已風(fēng)光不再。從醫(yī)藥行業(yè)凈利潤(rùn)排名(申萬(wàn)一級(jí)行業(yè)-醫(yī)藥生物)來看，公司已從2009年的行業(yè)第2名，下滑到2011年的第5名。
